University of Colorado
New Bladder Cancer Molecular Classification Predicts Response to Common Immunotherapy
The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.
COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials
The pandemic has underscored the importance of "bringing the trial to the patient," a concept that is likely to persist, particularly in precision oncology.
ROS1 Cancer Model Project Demonstrates Power of Patient Advocacy
The ROS1ders advocacy group is 500 patients strong and they are helping researchers establish cell lines to improve understanding of rare ROS1-positve cancers.
Treatment biomarkers for small cell lung cancer have been nearly non-existent, but researchers are beginning to find ones that mark PARP inhibitor response.